LAUSR

1 Matsuura T, Hayashida M, Saeki I, Taguchi T. The risk factors of persistent thrombocytopenia and splenomegaly after liver transplantation. Pediatr. Surg. Int. 2010; 26: 1007–10. 2 Kim ES. Lusutrombopag: first global approval. Drugs 2016; 76: 155–8. 3 Sato S, Miyake T, Kataoka M et al. Efficacy of repeated lusutrombopag administration for thrombocytopenia in a patient scheduled for invasive hepatocellular carcinoma treatment. Intern. Med. 2017; 56: 2887–90. 4 Sakamaki A, Watanabe T, Abe S et al. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient. Clin. J. Gastroenterol. 2017; 10: 261–4. 5 Fujita M, Abe K, Hayashi M, Okai K, Takahashi A, Ohira H. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization. Fukushima J. Med. Sci. 2017; 63: 165–71.